Intramuscular renin-angiotensin system is activated in human muscular dystrophy

Journal of the Neurological Sciences

Volumn 280, Issue 1-2, 2009, Pages 40-48

  Sun, Guilian ^a,b   Haginoya, Kazuhiro ^a,c   Dai, Hongmei ^a   Chiba, Yoko ^a   Uematsu, Mitsugu ^a   Hino Fukuyo, Naomi ^a   Onuma, Akira ^c   Iinuma, Kazuie ^d   Tsuchiya, Shigeru ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c Takuto Rehabilitation Center for Children   (Japan)

^d Ishinomaki Red Cross Hospital   (Japan)

Author keywords

Angiotensin converting enzyme; Angiotensin II; Angiotensin receptor; Muscular dystrophy; Renin angiotensin system; Transforming growth factor beta1

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; TRANSFORMING GROWTH FACTOR BETA1;

ANTIBODY LABELING; ARTICLE; BECKER MUSCULAR DYSTROPHY; BLOOD VESSEL; BRAIN NUCLEUS; CELL ACTIVATION; CELL INFILTRATION; CELL REGENERATION; CELLULAR DISTRIBUTION; CHILD; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CYTOPLASM; DUCHENNE MUSCULAR DYSTROPHY; ENDOMYSIUM; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; FIBROGENESIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; INFANT; MACROPHAGE; MALE; MUSCLE BIOPSY; MUSCLE BLOOD VESSEL; MUSCLE CELL; MUSCLE NECROSIS; MUSCULAR DYSTROPHY; NEUROMUSCULAR SYNAPSE; NEWBORN; PERIMYSIUM; PERIPHERAL NERVE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

BLOOD VESSELS; CHILD; CHILD, PRESCHOOL; ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; INFANT; MACROPHAGES; MALE; MUSCLES; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, DUCHENNE; NEUROMUSCULAR JUNCTION; PEPTIDYL-DIPEPTIDASE A; PERIPHERAL NERVES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; REGENERATION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 63349085819     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.01.020     Document Type: Article

References (52)

1. Bernasconi P., Torchiana E., Confalonieri P., Brugnoni R., Barresi R., Mora M., et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 96 (1995) 1137-1144
2. Zhao Y., Haginoya K., Sun G., Dai H., Onuma A., and Iinuma K. Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study. J Pathol 201 (2003) 149-159
3. D'Amore P.A., Brown Jr. R.H., Ku P.T., Hoffman E.P., Watanabe H., Arahata K., et al. Elevated basic fibroblast growth factor in the serum of patients with Duchenne muscular dystrophy. Ann Neurol 35 (1994) 362-365
4. Sander M., Chavoshan B., Harris S.A., Iannaccone S.T., Stull J.T., Thomas G.D., et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 97 (2000) 13818-13823
5. Rodriguez M.C., and Tarnopolsky M.A. Patients with dystrophinopathy show evidence of increased oxidative stress. Free Radic Biol Med 34 (2003) 1217-1220
6. Spencer M.J., and Tidball J.G. Do immune cells promote the pathology of dystrophin-deficient myopathies?. Neuromuscul Disord 11 (2001) 556-564
7. Gorospe J.R., Tharp M.D., Hinckley J., Kornegay J.N., and Hoffman E.P. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci 122 (1994) 44-56
8. Lindahl M., Backman E., Henriksson K.G., Gorospe J.R., and Hoffman E.P. Phospholipase A2 activity in dystrophinopathies. Neuromuscul Disord 5 (1995) 193-199
9. Chen Y.W., Nagaraju K., Bakay M., McIntyre O., Rawat R., Shi R., et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65 (2005) 826-834
10. Rodriguez-Barbero A., Obreo J., Yuste L., Montero J.C., Rodriguez-Pena A., Pandiella A., et al. Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. FEBS Lett 513 (2002) 282-288
11. Li Y., Foster W., Deasy B.M., Chan Y., Prisk V., Tang Y., et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 164 (2004) 1007-1019
12. Allen R.E., and Boxhorn L.K. Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. J Cell Physiol 133 (1987) 567-572
13. Weber K.T. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 17 (1997) 467-491
14. Jonsson J.R., Clouston A.D., Ando Y., Kelemen L.I., Horn M.J., Adamson M.D., et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121 (2001) 148-155
15. Bullock G.R., Steyaert I., Bilbe G., Carey R.M., Kips J., De Paepe B., et al. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol 115 (2001) 117-124
16. Tomita H., Egashira K., Ohara Y., Takemoto M., Koyanagi M., Katoh M., et al. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32 (1998) 273-279
17. Noble N.A., and Border W.A. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target?. Semin Nephrol 17 (1997) 455-466
18. Lijnen P.J., Petrov V.V., and Fagard R.H. Induction of cardiac fibrosis by angiotensin II. Methods Find Exp Clin Pharmacol 22 (2002) 709-723
19. Sadoshima J., and Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73 (1993) 413-423
20. Kagami S., Border W.A., Miller D.E., and Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93 (1994) 2431-2437
21. Cohn R.D., van Erp C., Habashi J.P., Soleimani A.A., Klein E.C., Lisi M.T., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13 (2007) 204-210
22. Sundberg C., Ivarsson M., Gerdin B., and Rubin K. Pericytes as collagen-producing cells in excessive dermal scarring. Lab Invest 74 (1996) 452-466
23. Jones A., and Woods D.R. Skeletal muscle RAS and exercise performance. Int J Biochem Cell Biol 35 (2003) 855-866
24. Schaufelberger M., Drexler H., Schieffer E., and Swedberg K. Angiotensin-converting enzyme gene expression in skeletal muscle in patients with chronic heart failure. J Card Fail 4 (1998) 185-191
25. Malendowicz S.L., Ennezat P.V., Testa M., Murray L., Sonnenblick E.H., Evans T., et al. Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure. Circulation 102 (2000) 2210-2213
26. Eley H.L., and Tisdale M.J. Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J Biol Chem 282 (2007) 7087-7097
27. Delafontaine P., and Akao M. Angiotensin II as candidate of cardiac cachexia. Curr Opin Clin Nutr Metab Care 9 (2006) 220-224
28. Russell S.T., Wyke S.M., and Tisdale M.J. Mechanism of induction of muscle protein degradation by angiotensin II. Cell Signal 18 (2005) 1087-1096
29. Matsusaka T., Hymes J., and Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 7 (1996) 2025-2043
30. Ryan J.W., Ryan U.S., Schultz D.R., Whitaker C., and Chung A. Subcellular localization of pulmonary antiotensin-converting enzyme (kininase II). Biochem J 146 (1975) 497-499
31. Vaghy P.L., Russell J.S., Lantry L.E., Stephens R.E., and Ward P.E. Angiotensin and bradykinin metabolism by peptidases identified in cultured human skeletal muscle myocytes and fibroblasts. Peptides 16 (1995) 1367-1373
32. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83 (1998) 1182-1191
33. Allen A.M., Zhuo J., and Mendelsohn F.A. Localization and function of angiotensin AT1 receptors. Am J Hypertens 13 (2000) 31S-38S
34. Qi J.S., Minor L.K., Smith C., Hu B., Yang J., Andrade-Gordon P., et al. Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors. Peptides 26 (2005) 683-690
35. Sun Y., and Weber K.T. Infarct scar: a dynamic tissue. Cardiovasc Res 46 (2000) 250-256
36. Nio Y., Matsubara H., Murasawa S., Kanasaki M., and Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95 (1995) 46-54
37. Finckenberg P., Inkinen K., Ahonen J., Merasto S., Louhelainen M., Vapaatalo H., et al. Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 163 (2003) 355-366
38. Igarashi A., Nashiro K., Kikuchi K., Sato S., Ihn H., Fujimoto M., et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 106 (1996) 729-733
39. Sun G., Haginoya K., Wu Y., Chiba Y., Nakanishi T., Onuma A., et al. Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy. J Neurol Sci 267 (2008) 48-56
40. Schorb W., Booz G.W., Dostal D.E., Conrad K.M., Chang K.C., and Baker K.M. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 72 (1993) 1245-1254
41. Gordon S.E., Davis B.S., Carlson C.J., and Booth F.W. ANG II is required for optimal overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab 280 (2001) 150-159
42. Wang B.W., Chang H., Kuan P., and Shyu K.G. Angiotensin II activates myostatin expression in cultured rat neonatal cardiomyocytes via p38 MAP kinase and myocyte enhance factor 2 pathway. J Endocrinol 197 (2008) 85-93
43. Bradley L., Yaworsky P.J., and Walsh F.S. Myostatin as a therapeutic target for musculoskeletal disease. Cell Mol Life Sci 65 (2008) 2119-2124
44. McCroskery S., Thomas M., Maxwell L., Sharma M., and Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 162 (2003) 1135-1147
45. Zhu J., Li Y., Shen W., Qiao C., Ambrosio F., Lavasani M., et al. Relationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosis. J Biol Chem 282 (2007) 25852-25863
46. Gallinat S., Yu M., Dorst A., Unger T., and Herdegen T. Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res Mol Brain Res 57 (1998) 111-122
47. Bleuel A., and Monard D. Regulation of protease nexin-1 and angiotensin II receptor subtype 1 expression: inverse relationship in experimental models of nerve injury. J Neurosci Res 42 (1995) 562-570
48. Zhou A., Yu L., Li J., Zhang J., and Wang H. Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor. Hypertens Res 23 (2000) 391-397
49. Molteni A., Moulder J.E., Cohen E.F., Ward W.F., Fish B.L., Taylor J.M., et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 76 (2000) 523-532
50. Zaman A.K., Fujii S., Sawa H., Goto D., Ishimori N., Watano K., et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation 103 (2001) 3123-3128
51. Border W.A., and Noble N.A. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 54 (1998) 1390-1391
52. Yu L., Noble N.A., and Border W.A. Therapeutic strategies to halt renal fibrosis. Curr Opin Pharmacol 2 (2002) 177-181